An Indian study has found distinct gut microbiome patterns in people with Parkinson’s disease, including increased levels of several bacterial groups associated with inflammation and reduced levels of other bacteria linked to gut health. Researchers from the Cochin University of Science and Technology (CUSAT) and the Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) studied patients in Kerala to investigate how intestinal microbes may be connected to the neurological disorder.
Published in npj Parkinson’s Disease on October 21, 2026, the research compared stool samples from 65 Parkinson’s patients and 65 healthy individuals. The researchers identified differences in bacterial composition and predicted microbial functions associated with neurotransmitters, amino acids and energy metabolism. The findings could guide further research into Parkinson’s disease, but they do not establish that gut bacteria cause the condition or that changing the microbiome can prevent or cure it.
Key Takeaways
- Indian research: Scientists studied 65 people with Parkinson’s disease and 65 healthy controls in Kerala.
- Inflammation-associated bacteria: Several bacterial groups were more abundant in the Parkinson’s group.
- Reduced beneficial bacteria: Some bacteria associated with gut health and anti-inflammatory functions were less abundant.
- Gut–brain connection: Predicted microbial functions were linked to pathways involving dopamine, glutamate and GABA.
- Potential future applications: The findings could help researchers investigate microbiome-based diagnostic tools and treatments.
- Important limitation: The study identified associations, not proof that particular bacteria cause Parkinson’s disease.
What Did the Indian Study Find?
The research, published in the journal npj Parkinson’s Disease, examined whether people with Parkinson’s disease had a different gut microbiome from healthy individuals.
The gut microbiome consists of bacteria and other microorganisms living in the digestive tract. These organisms help process food, produce metabolites and interact with the body’s immune system. Researchers are increasingly studying whether changes in the microbiome are associated with conditions affecting organs beyond the digestive system.
In the Kerala study, researchers used 16S ribosomal RNA gene sequencing to examine bacterial communities in stool samples. They then compared microbial composition between the two groups and used computational methods to investigate potential relationships between bacterial patterns and biological pathways.
The analysis found differences in both bacterial abundance and the overall composition of gut microbial communities. The Parkinson’s group showed higher levels of several bacterial groups classified by the researchers as potentially pro-inflammatory, alongside lower levels of some bacteria associated with beneficial gut functions.
The findings provide population-specific evidence of gut microbiome differences in Parkinson’s disease. They also support further investigation into how gut microbes, intestinal health and neurological processes might interact.
Which Gut Bacteria Were Associated With Parkinson’s Disease?
The study identified several bacterial groups whose relative abundance differed between Parkinson’s patients and healthy controls.
| Bacterial group | Finding in the study | Potential significance |
|---|---|---|
| Akkermansia | Higher abundance in the Parkinson’s group | May be relevant to interactions between gut microbes and intestinal health |
| Bifidobacterium | Higher abundance | A reminder that bacterial effects depend on species, strains and context; this genus is not universally harmful |
| Escherichia-Shigella | Higher abundance | Includes bacteria associated with intestinal inflammation and infection |
| Collinsella | Higher abundance | Has been investigated in relation to inflammatory and metabolic processes |
| Lachnospira | Lower abundance | Some members of this group contribute to beneficial fermentation processes |
| Agathobacter | Lower abundance | Associated with microbial metabolism and the production of short-chain fatty acids |
| Prevotella | Lower abundance | A diverse genus whose associations with health depend on species and context |
Source: The published research in npj Parkinson’s Disease.
These findings should not be interpreted as a list of bacteria that are always harmful or beneficial. A bacterial genus can contain species with different biological effects, and its significance may depend on the surrounding microbial community, diet and an individual’s health.
The researchers also reported differences involving other bacterial groups, including members of Enterobacterales and Eggerthellaceae. Together, these changes suggest that Parkinson’s disease is associated with a shift in the composition of the gut microbiome rather than a single identifiable bacterial cause.
How Could Gut Bacteria Be Connected to Parkinson’s Disease?
Parkinson’s disease is a progressive neurological disorder associated with the loss of dopamine-producing neurons and the accumulation of abnormal alpha-synuclein protein in the nervous system. Common symptoms include tremors, stiffness, slowed movement and problems with balance.
The digestive system may also be involved in the disease process. Constipation and other gastrointestinal symptoms can appear years before some of the better-known movement symptoms.
Scientists are investigating whether changes in gut bacteria could influence inflammation, intestinal barrier function and communication between the digestive system and the brain. This network of interactions is commonly described as the gut–brain axis.
Some gut bacteria produce short-chain fatty acids, including butyrate, through the fermentation of dietary fibre. These compounds can support intestinal barrier function and influence immune activity. A reduction in certain short-chain-fatty-acid-producing bacteria could therefore be relevant to gut health.
However, the relationship is complex. The Kerala study identified microbial patterns associated with Parkinson’s disease, but it did not directly establish a chain of events in which a particular bacterium causes intestinal damage, triggers brain inflammation and produces Parkinson’s symptoms.
What the Study Says About Brain Chemicals
The researchers also used predictive functional profiling to examine how the observed microbial differences might relate to biological pathways.
Their analysis identified potential changes in pathways involving dopamine, glutamate and gamma-aminobutyric acid (GABA). These chemicals play important roles in nervous-system signalling and brain function.
Dopamine is especially relevant to Parkinson’s disease because the disorder affects neurons involved in producing and using this neurotransmitter. Glutamate and GABA are also important in regulating communication between nerve cells.
The findings suggest that microbial differences could be connected to metabolic processes relevant to neurological function. However, predictive profiling estimates potential microbial functions from sequencing data; it does not directly measure every metabolic process occurring in the gut or establish that microbial changes alter neurotransmitter levels in the brain.
More detailed studies will be needed to test these possible mechanisms and determine whether they contribute to disease development or progression.
How the Research Could Help Diagnose or Treat Parkinson’s Disease
The researchers hope that identifying microbiome patterns associated with Parkinson’s disease could support future diagnostic research and investigations into treatments targeting gut health.
One potential application is a stool-based test that examines bacterial patterns alongside other clinical information. Such a test might eventually help researchers identify biological signatures associated with the disease or particular symptom profiles.
Another area of interest is whether dietary interventions, microbial therapies or other approaches to gut health could improve gastrointestinal symptoms or influence disease progression.
Neither application is ready for routine clinical use on the basis of this study alone. A useful diagnostic test would need to demonstrate reliable performance in larger and more diverse populations. Potential microbiome treatments would require carefully controlled clinical trials to establish safety and effectiveness.
Patients should not take antibiotics, probiotics or other supplements specifically to treat Parkinson’s disease based solely on these findings. Anyone experiencing neurological symptoms should seek medical assessment rather than relying on a commercial microbiome test.
Study Limitations and What Researchers Need to Investigate Next
The study provides useful evidence, but several limitations affect how its findings should be interpreted.
First, the research involved 130 participants from a specific population in Kerala. Gut microbiomes can vary with diet, age, medication, lifestyle, geography and other health conditions. Results from this group may not apply equally to every population.
Second, observational comparisons cannot determine whether bacterial differences contribute to Parkinson’s disease, arise as a consequence of the disease or reflect other factors associated with it. Changes in diet, physical activity, medication and gastrointestinal function could influence the microbiome.
Third, 16S rRNA sequencing is useful for examining bacterial composition but does not provide the same level of functional detail as comprehensive metagenomic and metabolomic analyses. Predictive functional profiling can suggest possible mechanisms, but these require direct testing.
Larger studies across multiple locations, longitudinal research following participants over time and laboratory experiments will be important for determining whether the identified microbial signatures have a causal role.
The Bigger Picture
The Kerala study adds to an expanding body of research exploring the relationship between gut microbes and neurological disorders. It provides evidence that people with Parkinson’s disease can have distinct intestinal bacterial profiles and that these differences may be associated with inflammatory and metabolic processes.
The broader significance lies in the possibility that the gut–brain axis could eventually help researchers understand why Parkinson’s disease develops differently among individuals. But translating microbiome research into clinical practice will require reproducible biomarkers, clear biological mechanisms and evidence from clinical trials.
FAQs
1. What did the Indian study find about gut bacteria and Parkinson’s disease?
Researchers found differences in gut bacterial composition between 65 Parkinson’s patients and 65 healthy controls. Several potentially inflammation-associated bacterial groups were more abundant, while some bacteria linked to beneficial gut functions were less abundant.
2. Do gut bacteria cause Parkinson’s disease?
The study does not prove that gut bacteria cause Parkinson’s disease. It identifies associations that may help researchers investigate possible mechanisms involving inflammation, intestinal health and the gut–brain axis.
3. Which bacteria were associated with Parkinson’s disease?
The study reported higher abundance of groups including Akkermansia, Bifidobacterium, Escherichia-Shigella and Collinsella, alongside lower abundance of groups including Lachnospira, Agathobacter and Prevotella. These associations do not mean that every member of a particular genus is harmful or beneficial.
4. Can probiotics prevent or treat Parkinson’s disease?
This study does not establish that probiotics prevent or treat Parkinson’s disease. Although microbiome-targeted treatments are an active area of research, their effectiveness for Parkinson’s disease must be established through appropriate clinical trials.
5. Could a gut bacteria test diagnose Parkinson’s disease in the future?
Possibly, but the findings are preliminary. Researchers would need to validate any proposed microbial signature in larger, independent populations and show that it can reliably distinguish Parkinson’s disease from other conditions.
Looking Ahead
Researchers will need to determine whether the bacterial patterns observed in Kerala can be reproduced across different populations and whether they change as Parkinson’s disease progresses. Longitudinal studies and direct measurements of microbial metabolites could help establish whether the microbiome contributes to the disease process or mainly reflects changes associated with it.
For now, the study offers a promising research direction rather than a new clinical test or treatment. A better understanding of the gut–brain connection could eventually support earlier detection or complementary treatment strategies, but those possibilities will depend on stronger evidence and carefully designed clinical research.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
